# Prothena (PRTA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PRTA
## Company Profile
- Ticker: PRTA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Ireland
- Tags: CNS
## Stock Data
- Close: 8.61 USD
- Market cap: 481126248.03 USD
- Last updated: 2026-10-08
## Business Overview
### Protein-Dysregulation Biotechnology Company
Prothena develops therapies for neurodegenerative and rare peripheral amyloid diseases driven by misfolded or accumulated proteins. Its research focuses on antibodies and targeted biologics that remove pathogenic protein species or interfere with disease-associated aggregation.
### Parkinson's Disease Collaboration
Prasinezumab is an alpha-synuclein antibody being developed with Roche for early Parkinson's disease. The program is intended to slow disease progression by targeting a pathogenic form of alpha-synuclein and has advanced into the large Phase 3 PARAISO trial.
### Amyloid and Tau Programs
Coramitug, acquired by Novo Nordisk, is designed to deplete non-native transthyretin in ATTR cardiomyopathy. Moponetug, partnered with Bristol Myers Squibb, targets a disease-relevant region of tau for early Alzheimer's disease, giving Prothena exposure to two major protein-aggregation disorders through externally funded development.
### CYTOPE Technology
The CYTOPE platform combines disease-selective binding with cell-internalizing capabilities to reach intracellular pathological proteins. Prothena is applying the technology to targets including TDP-43 in amyotrophic lateral sclerosis and other neurodegenerative diseases.
### Partner-Funded Business Model
Much of Prothena's clinical pipeline is developed by Roche, Novo Nordisk, and Bristol Myers Squibb. This model reduces direct late-stage spending while preserving potential milestone payments and royalties, with wholly owned research focused on new protein targets and platform programs.
## Why The Stock Is Moving

As of Oct 8, 2026, PRTA closed up 1.53% at $8.61. No new same-company headline was identified in the current news window.

## Future Catalysts

- Bristol Myers Squibb decision on advancement of PRX019 by year-end 2026.
- Primary completion of the Phase 2 TargetTau-1 trial of moponetug in early Alzheimer's disease in the first half of 2027.
- Primary completion of the coramitug PET/CT biodistribution and amyloid-depletion study in 2027.
- Primary completion of the Phase 3 PARAISO trial of prasinezumab in early Parkinson's disease in 2029.
- Primary completion of the Phase 3 CLEOPATTRA trial of coramitug in ATTR cardiomyopathy in 2029.

## Recent News
- 2022-10-27 20:05 EST — [Prothena to Report Third Quarter 2022 Financial Results on November 3rd](https://biopharmsignal.com/news/PRTA/prothena-to-report-third-quarter-2022-financial-results-on-november-3rd-7aeda7c3) — Source: Prothena
- 2022-09-01 20:20 EST — [Prothena to Participate in Upcoming Healthcare Conferences](https://biopharmsignal.com/news/PRTA/prothena-to-participate-in-upcoming-healthcare-conferences-da2830cc) — Source: Prothena
- 2022-09-01 20:05 EST — [Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors](https://biopharmsignal.com/news/PRTA/prothena-announces-appointment-of-biotechnology-industry-leader-helen-s-kim-to-i-d1e6f1fc) — Source: Prothena
- 2022-08-08 20:05 EST — [Prothena Reports Second Quarter 2022 Financial Results and Business Highlights](https://biopharmsignal.com/news/PRTA/prothena-reports-second-quarter-2022-financial-results-and-business-highlights-432f19fa) — Source: Prothena
- 2022-08-02 20:05 EST — [Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/PRTA/prothena-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-fef1ae61) — Source: Prothena